Dose distribution verification for GYN brachytherapy using EBT Gafchromic film and TG-43 calculation by Gholami, S. et al.
reports of practical oncology and radiotherapy 2 1 ( 2 0 1 6 ) 480–486
Available  online  at  www.sciencedirect.com
ScienceDirect
jo ur nal home p ag e: ht tp : / /www.e lsev ier .com/ locate / rpor
Original research article
Dose  distribution  veriﬁcation  for GYN
brachytherapy using  EBT Gafchromic  ﬁlm  and
TG-43 calculation
Somayeh Gholamia,b, Hamid Reza Mirzaei c,∗, Ali Jabbary Arfaeec,
Ramin  Jaberib, Hassan Ali Nedaieb, Seied Rabi Mahdavid,
Eftekhar Rajab Bolookatc, Ali S. Meigooni e
a Department of Medical Physics and Biomedical Engineering, Faculty of Medicine, Tehran University of Medical
Sciences, Tehran, Iran
b Radiation Oncology Department, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
c Radiation Oncology Department, Shohada e Tajrish Hospital, Cancer Research Center, Shahid Beheshti University
of Medical Sciences, Tehran, Iran
d Department of Medical Physics, Iran University of Medical Sciences, Tehran, Iran
e Comprehensive Cancer Centers of Nevada, Las Vegas, NV, United States
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 23 October 2015
Received in revised form
20  January 2016
Accepted 26 June 2016
Available online 18 July 2016
Keywords:
QA brachytherapy phantom
Film dosimetry
GZP6 HDR system
Selectron LDR system
a  b  s  t  r  a  c  t
Aim: Veriﬁcation of dose distributions for gynecological (GYN) brachytherapy implants using
EBT Gafchromic ﬁlm.
Background: One major challenge in brachytherapy is to verify the accuracy of dose distri-
butions calculated by a treatment planning system.
Materials and methods: A new phantom was designed and fabricated using 90 slabs of
18  cm × 16 cm × 0.2 cm Perspex to accommodate a tandem and Ovoid assembly, which is
normally used for GYN brachytherapy treatment. This phantom design allows the use of
EBT Gafchromic ﬁlms for dosimetric veriﬁcation of GYN implants with a cobalt-60 HDR sys-
tem or a LDR Cs-137 system. Gafchromic ﬁlms were exposed using a plan that was designed
to  deliver 1.5 Gy of dose to 0.5 cm distance from the lateral surface of ovoids from a pair
of  ovoid assembly that was used for treatment vaginal cuff. For a quantitative analysis of
the  results for both LDR and HDR systems, the measured dose values at several points ofTG-43 interests were compared with the calculated data from a commercially available treatment
planning system. This planning system was utilizing the TG-43 formalism and parameters
for  calculation of dose distributions around a brachytherapy implant.Results: The results of these investigations indicated that the differences between the cal-
culated and measured data at different points were ranging from 2.4% to 3.8% for the LDR
Cs-137 and HDR Co-60 systems, respectively.
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versity  of Medical Sciences, Tehran, Iran. Tel.:+98 2161192500; fax: +98 2161192501.
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Conclusion: The EBT Gafchromic ﬁlms combined with the newly designed phantom could
be  utilized for veriﬁcation of the dose distributions around different GYN implants treated
with  either LDR or HDR brachytherapy procedures.
© 2016 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
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g.  Background
s radiation therapy techniques become more  complex, the
uality assurance (QA) techniques have to be changed to
rovide a sound and practical method of veriﬁcation of treat-
ent delivery in order to reduce errors during radiation
herapy.1 A QA progress needs to be adopted for complex
rachytherapy treatment techniques, particularly when it
nvolves treatment with a complex gynecologic (GYN) system.
GYN brachytherapy treatments for the cervix, vaginal and
ndometrial cancers have been commonly used for over 100
ears.2 Accuracy of dose calculation plays a vital role in the
rachytherapy treatment planning. Experimental veriﬁcation
f dose accuracy is one of possible QA procedures for determi-
ation of over-dose or under-dose area in the brachytherapy
lanning volume. However, this technique faces several chal-
enges related to the measurements of dose distributions in a
igh-gradient region. One of the important criteria for these
xperimental setups is to have a dosimeter with high spa-
ial resolution such as Gafchromic ﬁlms. Gafchromic ﬁlms are
eing used as 2D dosimeters by several investigators in various
ypes of applications.3
Different investigators had demonstrated the useful-
ess of the EBT Gafchromic ﬁlms for brachytherapy source
osimetry.4 These ﬁlms require no chemical processing and
hey are insensitive to ambient light. Therefore, they can be
ut to the shape of the experimental geometry for the best
epresentation of a dosimetric setup.
.  Aim
eriﬁcation of dose distributions for gynecological (GYN)
rachytherapy implants using EBT Gafchromic ﬁlm.
.  Materials  and  methods
BT Gafchoromic ﬁlm dosimetry for two different brachyther-
py systems for GYN treatment were considered in this
tudy: the GZP6 high dose rate (HDR) 60Co brachytherapy unit
hat was introduced by Nuclear Power Institute of China for
rachytherapy procedures,5 and the Selectron low-dose-rate
LDR) 137Cs remote afterloading system distributed by Nucle-
ron (Nucletron BV, Veenendaal, The Netherlands).6
.1.  GZP6  HDR  system
ZP6 afterloading unit (Nuclear Power Institute of China) with
DR 60Co sources has one stepping source and ﬁve non-
tepping source-braids.7 The GZP6 treatment planning system
s able to produce dose distributions in the transverse and lon-
itudinal planes. It calculates dose using the superpositiondose calculation technique. This system could be used
for intracavitary treatment of cervical, vaginal, endome-
trial, rectal, esophageal and nasopharyngeal malignancies.
The sources in this system were consisted of 60Co active
pellets (3.5 mm long and 1.5 mm diameter) sealed by tita-
nium capsules and spherical stainless steel inactive pellets
(1.5 mm diameter) which were covered by a steel spring.8 TG-
43 recommended dosimetric characteristics of the sources
in this system have been evaluated by several different
investigators.7–9
In this study channels 3 and 4 of GZP6 HDR system were
utilized to deliver 1.5 Gy dose to 0.5 cm distance from the lat-
eral surface of ovoids within 4.62 min. Each of the channels
3 and 4 contains one stationary active pellet (they are nearly
identical in their source strength and geometry) and they can
be used in the ovoids.
3.2.  Selectron  LDR  system
Selectron Cs-137 LDR system has some active pellet spherical
sources (supplied by Amersham Corporation, Louisville, CO)
and inactive or dummy pellets in an applicator set.10 Differ-
ent combinations of active and inactive pellets are used for
GYN cancer. The Nucletron PLATO treatment planning system
(TPS) calculates the dose delivered by the unit at the point of
interest.10 The TPS determines the dose distribution around
different combinations of sources and spacers by assuming
each active pellet as a point source, using the superposition
dose calculation technique.
The Selectron unit consists of spherical Cs-137 pellets
composed of 1.5 mm active source core of ceramic, encapsu-
lated in 0.5 mm steel, with a total diameter of 2.5 mm.11 In
addition, this system contains some non-active pellets as a
dummy, with the same dimensions and chemical composi-
tion as the active pellets.6 Liu et al. have published the TG-43
recommended dosimetric characteristics of the sources in this
system.12
In this study, from a set of 8 pellets, numbers 2–7 are con-
sidered active, and the remainders are non-active, in order
to deliver 1.5 Gy of dose to 0.5 cm distance from the lateral
surface of ovoids within 1.01 h.
3.3.  EBT  Gafchromic  ﬁlm  dosimetry
The new phantom was designed and fabricated from 90 slabs
of 18 cm × 16 cm × 0.2 cm Perspex to accommodate GYN appli-
cators (tandem and ovoid). The composition of the Perspex
taken to be H, 8%; C, 60%; O, 32%, with a density of 1.18 g/cm3.13
This conﬁguration enables us to verify the dose distributions
around the applicator with a high spatial resolution. Fig. 1
shows the schematic diagram of this phantom with its layers
and the ovoid applicator which is placed in the phantom.
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Fig. 1 – Schematics of different layers of the phantom and
Oviod applicator.
The thin layer of the slabs was carefully machined to
accommodate layers of Gafchromic ﬁlms in between the slabs
for radiation dosimetry. The irradiated ﬁlms were cut with
scissors in various sizes and shape to match the curvature and
location of the applicator. Large size (3 cm diameter) ovoids
were selected for both GZP6 and Selectron machines. With this
assembly, EBT Gafchromic ﬁlms14 were exposed using a plan
with 1.5 Gy dose deliveries to 0.5 cm distance from the lateral
surface of the ovoids for both units.
For a quantitative evaluation, only a pair of the ovoids has
been used in order to be able to reproduce the experimen-
tal setup and geometry of the assembly for repetition of the
measurement, and also for different source types.
Fig. 2 shows the schematic diagram of the points of interest
and the applicator. These points of interest include, point “D”
representing vaginal mucosa, located at 0.5 cm distance from
the lateral surface of the ovoid and “F” that was located at 1 cm
distance from the lateral surface of the ovoid.
The differences between the planned and measured data
demonstrate the accuracy of the planned dose distribution
Fig. 2 – Schematic diagram of the Ovoid applicators and
calculated points relative to the applicator. D and F show
points of interest for dose calculation (graphs are not to the
scale).iotherapy 2 1 ( 2 0 1 6 ) 480–486
around applicators. These measurements were repeated at
least 3 times to improve the statistical ﬂuctuation of the ﬁnal
data.
Samples of EBT Gafchromic ﬁlms were calibrated to deter-
mine the sensitivity curve (i.e. response vs. dose). A calibrated
teletherapy cobalt-60 system was chosen for calibration
process of the Gafchromic ﬁlms. For 137Cs dose calcula-
tion because of energy dependence of Gafchromic ﬁlms,15
response curve and the energy dependence of Gafchromic
ﬁlm for different radiation energies from Chiu-Tsao study was
considered.16 Calibration curve and its relative energy depend-
ence coefﬁcient were used for the analysis of the irradiated
ﬁlms around the GYN applicator for 60Co and 137Cs sources
within the new phantom design. 130 pieces of EBT ﬁlms with
size of 2 cm × 1.5 cm were selected for calibrating samples
using a teletherapy cobalt-60 system in the range of 25–800 cGy
dose with 25 cGy interval. These ﬁlms were exposed at 1 cm
depth in a 30 cm × 30 cm × 10 cm slab Perspex layers with a
20 cm × 20 cm radiation ﬁeld size. After 24 h from exposure,
ﬁlms were scanned using a ﬂatbed Microtek scanner (model:
ScanMaker 9800XL, Microtek Laboratories, Inc., Dayton, OH).
Since the peak absorption of the radiochromic ﬁlm is in the
red region of the visible spectrum (636 nm), extraction of the
red channel from the RGB image  can improve scanner sensitiv-
ity. As suggested in the guideline of the Gafchromic ﬁlms, the
irradiated ﬁlms for both calibration and measurement process
were scanned in the landscape orientation. For ﬁlm calibration
and both Unit experimental measurements, ﬁlms were used
from the same batch.
In addition, we complied with the recommendation on pro-
jecting the ﬁlm orientation on small pieces that were used for
radiation dosimetry. Both calibrations and experimental ﬁlm
scanning were performed using 100 dpi resolutions.
The pixel values were obtained from IMAGEJ software (Java-
based image  processing program, National Institute of Health).
The scanners allow the acquisition of transmission scans in
up to 16 bits per color. In Eq. (1) net optical density (NOD) was
calculated from subtraction of ODirr and ODunirr which repre-
sented the optical densities of un-irradiated and irradiated
ﬁlm, respectively:
NOD = ODirr − ODunirr =
[
−log10
(PVirr − PVdark)
(PVblank − PVdark)
]
−
[
−log10
(PVunirr − PVdark)
(PVblank − PVdark)
]
(1)
where the PVirr, PVunirr, PVdark and PVblank represent the pixel
values measured in the irradiated ﬁlm, un-irradiated ﬁlm,
zero-light transmitted images of the opaque sheet scan and
blank, respectively.
The selected region of interest was a 2 mm × 2 mm in the
center of the ﬁlm piece to avoid optical density (OD) measure-
ment artifacts near ﬁlm edges.17
3.4.  TG-43  calculationThe task group 43 (TG-43) of the American Association
of Physicists in Medicine (AAPM) has published a protocol
regarding the brachytherapy dose calculation formalism.18
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G-43 formalism can also be used for veriﬁcation of experi-
ental dosimetry. Various investigators have determined the
osimetric characteristics of different brachytherapy sources
sing this recommendation.19,20 Dosimetric characteristics of
he single pellets from each system have been evaluated using
he TG-43 protocols by different investigators.12,21
For both Selectron and GZP6 unit ﬁlm dosimetry with the
ew phantom at multiple levels relative to the GYN applicators
ere done. We  compared dose calculation of ﬁlm dosimetry
rom some interesting points with treatment planning. TG-
3 calculation was considered for both sources. The phantom
aterial density (d = 1.18 g/cm3) was considered for TG-43 cal-
ulations of both sources.
TG-43 formalism was employed depending on dosimetric
arameters of 60Co and 137Cs sources.
These parameters consist of air kerma strength, dose
ate constant, geometry function, radial dose function and
nisotropy function. They are indicated in Eq. (2)18:
 · (r, ) = SK ·  · GL(r, )
GL(r0, 0)
·  g(r) · F(r, ) (2)
osimetric characterizations of GZP6 60Co HDR brachyther-
py for TG-43 calculation were used from Toosi’s study.22 So,
he superposition technique was used. Based on their study,
ose rate constant value of GZP6 is 1.04 cGy h−1 U−1. Radial
ose and 2D anisotropy functions were considered from their
onte Carlo simulation. TG-43 parameters of Cs-137 Selec-
ron LDR brachytherapy sources were considered from Sina’s
onte Carlo simulation.23 So, dose rate constant value for this
nit is 1.102 cGy h−1 U−1. We used air kerma strength (SK) from
reatment planning for dose calculation in Eq. (3) for Cs-137
electron sources. For Cs-137 Selectron, air kerma strength
SK) from treatment planning system was considered in TG-
3 calculation. While, for GZP6 system, air kerma strengths of
ources were measured using the ionization chamber dosime-
er.
.5.  GZP6  air  kerma  strength
he vendor of GZP6 has provided approximately 600 preplans
ithout providing the algorithms that had been used in these
alculations. The only parameter that was given, in addition
o the plans, was the source strengths for individual sources.
herefore, it was decided to verify the accuracy of this param-
ter. To investigate the air kerma strength of GZP6 unit, Monte
arlo simulation and practical measurement were utilized. In
ur calculation, it is considered that the date of practical SK
easurement, air kerma from Monte Carlo simulation and
reatment planning SK was the same.
For simulation, MCNP4C Code is used based on the tech-
ique that was published by Toosi et al. Self-absorption of the
ource core and its capsule were taken into account at their
tudy.7 For this part of our work, cylindrical rings with 0.5 cm
hickness and 0.5 cm length were simulated in the 1–25 cm
ransverse distance from the source center, in 1 cm incre-
ents. In ring cells, the F6 tally was used to calculate air kerma
n unit of MeV/g per photon in the ring cells. Source activ-
ty, self-absorption, number of disintegration for 60Co source,
ecay coefﬁcient based on cobalt-60 half time and date oftherapy 2 1 ( 2 0 1 6 ) 480–486 483
measurement, square of distance and other appropriate con-
version factors were multiplied by the value of the result from
Tally F6 to calculate SK. Photon primary history was 107 to
reduce statistical error to less than 1%. For both photons and
electrons the cutoff energy was deﬁned as 10 keV.
Air kerma strength of GZP6 unit was measured according
to the TECDOC-1274 technical document of the Interna-
tional Atomic Energy Agency (IAEA).24 For measurement of
air kerma, available 0.6 cm3 Farmer type ionization cham-
ber (FC65-G TNC/249 Scanditronix Wellhofer) was used with
0.551 g/cm3 build up cap and an electrometer (Scanditronix
Wellhofer). The chamber was calibrated by the SSDL lab-
oratory of Atomic Energy Organization of Iran (AEOI) for
standard ﬁeld of a teletherapy cobalt-60 machine with
ND,W = 4.83 cGy/nc. We used the multiple distance method and
readings of chamber in ampere at speciﬁed distances along
the perpendicular bisector of the line source were scored. The
exact position of the source was well deﬁned by using a mil-
limetric ruler and source autoradiography. Apparent distance
between the sensitive volume of the chamber and the center
of the source was measured. There is 1 mm offset in distance.
Measurements were performed in 1 cm intervals. In each posi-
tion, we  measured 3 times and made the average of values. To
approach SK, chamber reading in ampere was multiplied by
the chamber calibration value (ND,W), temperature and pres-
sure correction factor (KT,P), duration exposure and square of
the distance to the center of the source.
3.6.  Film  dosimetry  uncertainty  estimation
The overall accuracy of EBT ﬁlm measurements was  derived
using the method proposed by Devic et al.25 Statistical uncer-
tainty of ﬁlm response to the same value of dose is related
to some factors such as non-uniformity thickness in the sen-
sitive layer of the ﬁlms, uncertainties associated with the
scanning procedure and output variations of Linac during
exposure. In this study, we  considered two sources of uncer-
tainties. The ﬁrst one is related to netOD measurements
and the other is related to ﬁtting coefﬁcients in calibration
curves. Moreover, a special attention was paid to the distances
between the phantom’s edge and edge of the ﬁlm. The dis-
tance between the phantom slabs’ edge and the applicators
is 95 m.  Moreover, there is a 0.1 mm gap between the edge
of the machined ﬁlm and the phantom’s edge. Also, there is a
0.5 mm error in determining the position of points of interest.
The total dose uncertainty was calculated through the fol-
lowing equation:
Total =
√
2netOD + 2calib-fit + 2phantom-film (3)
4.  Results
4.1.  EBT  Gafchromic  ﬁlm  calibrationFig. 3 shows the calibration curve of the EBT Gafchromic ﬁlm
response, in terms of net optical density (NOD), as a function of
absorbed dose to water in the range of 25–800 cGy. The mea-
sured data were correlated using the following polynominal
484  reports of practical oncology and radiotherapy 2 1 ( 2 0 1 6 ) 480–486
Table 1 – Comparison between the measured and calculated dose values at different points around a typical applicator in
GYN implant of Selectron 137Cs LDR source.
Points Dose-
treatment
planning (cGy)
Dose-TG-43 (cGy) Dose-ﬁlm (cGy) Difference between
ﬁlm dosimetry and
TG-43 calculation (%)
Point D-L 150 144.3 145.8 +1
Point D-R 150 144.3 
Point F-L 100 93.5
Point F-R 100 93.5
Fig. 3 – Calibration curve for EBT Gafchromic ﬁlm response
(optical density) as function of the absorbed dose (cGy). The
error bars in this graph represent ±5%. The solid line on
this graph simply connects the data points.
between the measurement and simulation.function in Eq. (4) with R2 = 0.9837. Calibration coefﬁcient of
137Cs source was obtained from Chiu-Tsao’s study. For scanner
with red light relationship between the NOD response of the
EBT ﬁlm and source energy in MeV  (parameter x) is considered
as Eq. (5).
Dose (Gy) = 42.43NOD2 − 8.14NOD + 5.24 (4)NOD = −0.025x2 + 0.1165x + 0.869 (5)
Fig. 4 – Plot of the air kerma rate × d2 vs. distance d (cm) from the
5% statistical ﬂuctuation of the Farmer dosimetry.144.9 +0.4
95.8 +2.4
95.4  +2
So, there is 2% difference between 60Co with mean energy
1.25 MeV and 137Cs with energy 0.662 MeV. This difference
is employed for 137Cs ﬁlm dosimetry. There is a total of 5%
uncertainty that was employed for the results of dose mea-
surements.
4.2.  Selectron  LDR  brachytherapy
The value of reference air kerma rate for Selectron TG-43 dose
calculation is extracted from treatment planning and equal to
8876.74 Gy m2 h−1. The quantitative analysis of the measured
data for Selectron 137Cs LDR source and TG-43 dose calculation
is shown in Table 1. Results of Selectron unit show good agree-
ment (total difference is up to 6%) between ﬁlm dosimetry,
TG-43 dose calculation and treatment planning.
4.3.  GZP6  HDR  brachytherapy
Air kerma strength (SK) for GZP6 HDR brachytherapy sys-
tem from Monte Carlo code was obtained 4414 × 10−6 and
4077 × 10−6 Gy m2 h−1 for source of CH3 and CH4, respectively.
The value of measured air kerma strength was
obtained by taking into account the date of measurement
4207 × 10−6 ± 1% Gym2 h−1 for CH3 and 3864.5 × 10−6 ±
1% Gym2 h−1 for CH4. Fig. 4 shows results of SK measurement
by a multiple distance method. There is about 5.4% differenceTable 2 indicates the results of TG-43 dose calculations and
ﬁlm dosimetry. Maximum difference between ﬁlm dosimetry
and TG-43 was to 3.8%.
 source center. The error bars on this data points represent
reports of practical oncology and radiotherapy 2 1 ( 2 0 1 6 ) 480–486 485
Table 2 – Comparison between the measured and calculated dose values at different points around a typical applicator in
GYN implant of GZP6 60Co HDR source.
Points Dose-
treatment
planning (cGy)
Dose-TG-43 (cGy) Dose-ﬁlm (cGy) Difference between
ﬁlm dosimetry and
TG-43 calculation (%)
Point D-L 150 148.5 143.6 −3.3
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.  Conclusions
lthough the American Association of Physicists in Medicine
ask Group reports 56 and 59 provide reasonable guidance on
peciﬁc process of QA in brachytherapy,26,27 improved guid-
nce is needed for any treatment delivery system to minimize
ach individual treatment failure. In this project, the dose
istributions around the GYN applicators for two different
achines, Selectron LDR source and GZP6 HDR system were
easured using EBT Gafchoromic ﬁlm for a sample GYN setup.
he result shows good agreement between our ﬁlm dosimetry,
G-43 calculation and treatment planning (total difference is
p to 6%). In this study, it has been demonstrated that Per-
pex can be used as phantom material in brachytherapy. The
erspex material is denser than water, so it produces more
ttenuation of primary radiation but on the other hand, this
s compensated by an increase in scatter radiation under full
cattering conditions.28
These investigations have veriﬁed that using the
afchromic ﬁlm dosimetry technique together with the
ew phantom; one could examine the accuracy of dose
alculation at different distances to the GYN applicators. This
ystem has shown that in a high dose gradient region around
ompound applicators, users could verify the accuracy of dose
istribution with a technique that is clinically relevant and
ractical. Recently, there are some studies related to proper
hantoms for QA of brachytherapy systems.29,30 Comparing
hem with this phantom, different models of Gafchromic
lms can be used which are very convenient and reliable for
outine quality assurance. This assembly can be used at high
radient regions for periodic QA procedures.
onﬂict  of  interest
one.
inancial  disclosure
one.
cknowledgements
 hereby acknowledge Clinical Research Development Unit
CRDU) Shohada Tajrish hospital which was supported this
esearch.
The Radiotherapy Department of Shahid Beheshti Uni-
ersity at Shohada hospital sponsored the purchase of the
hantom materials and ﬁlms used in the investigations. The
1142.8 −3.8
95 −3
95.5 −2.5
authors would like to present their appreciation for Dr  Mehdi
Ghorbani for his invaluable contributions at different phases
of this project. In addition, the editorial comments and sug-
gestions by Dr Courtney Knaup for enhancing the quality of
the manuscript are greatly appreciated.
 e  f  e  r  e  n  c  e  s
1. Asnaashari K, Gholami S, Khosravi H. Lessons learnt from
errors in radiotherapy centers. Int J Radiat Res
2014;12(4):361–7.
2. Gerbaulet A. The GEC ESTRO handbook of brachytherapy; 2002.
3. Niroomand-Rad A, Blackwell CR, Coursey BM, et al.
Radiochromic ﬁlm dosimetry: recommendations of AAPM
radiation therapy committee task group 55. Med Phys
1998;25(11):2093–115.
4. Chiu-Tsao S-T, Medich D, Munro III J. The use of new
GAFCHROMIC® EBT ﬁlm for I125 seed dosimetry in Solid
Water® phantom. Med Phys 2008;35(8):3787–99.
5. Papagiannis P, Angelopoulos A, Pantelis E, Sakelliou L,
Karaiskos P, Shimizu Y. Monte Carlo dosimetry of 60Co HDR
brachytherapy sources. Med Phys 2003;30(4):712–21.
6. Sina S, Faghihi R, Meigooni AS, Mehdizadeh S, Shirazi MAM,
Zehtabian M. Impact of the vaginal applicator and dummy
pellets on the dosimetry parameters of Cs-137 brachytherapy
source. JACMP 2011;12(3).
7. Toossi MTB, Ghorbani M, Mowlavi AA, et al. Air kerma
strength characterization of a GZP6 Cobalt-60 brachytherapy
source. RPOR 2010;15(6):190–4.
8. Naseri A, Mesbahi A. Application of Monte Carlo calculations
for validation of a treatment planning system in high dose
rate brachytherapy. RPOR 2009;14(6):200–4.
9. Mesbahi A. Radial dose functions of GZP6 intracavitary
brachytherapy 60Co sources: treatment planning system
versus Monte Carlo calculations. IJRR 2008;5(4):181–6.
0. Fragoso M, Love P, Verhaegen F, et al. The dose distribution of
low dose rate Cs-137 in intracavitary brachytherapy:
comparison of Monte Carlo simulation, treatment planning
calculation and polymer gel measurement. PMB
2004;49(24):5459.
1. Grigsby PW, Williamson JF, Perez CA. Source conﬁguration
and dose rates for the Selectron afterloading equipment for
gynecologic applicators. Int J Radiat Oncol 1992;24(2):
321–7.
2. Liu L, Prasad SC, Bassano DA. Determination of 137Cs
dosimetry parameters according to the AAPM TG-43
formalism. Med Phys 2004;31(3):477–83.
3. Saidi P, Sadeghi M, Hosseini H, Tenreiro C.
Thermoluminescent and Monte Carlo dosimetry of
IR06-103Pd brachytherapy source. JACMP 2011;12(4).4. Sarfehnia A, Kawrakow I, Seuntjens J. Direct measurement of
absorbed dose to water in HDR I192r brachytherapy: water
calorimetry, ionization chamber, Gafchromic Film, and
TG-43. Med Phys 2010;37(4):1924–32.
d rad
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2486  reports of practical oncology an
5. Muench PJ, Meigooni AS, Nath R, McLaughlin W.  Photon
energy dependence of the sensitivity of radiochromic ﬁlm
and comparison with silver halide ﬁlm and LiF TLDs used for
brachytherapy dosimetry. Med Phys 1991;18(4):769–75.
6. Chiu-Tsao S-T, Ho Y, Shankar R, Wang L, Harrison LB. Energy
dependence of response of new high sensitivity radiochromic
ﬁlms for megavoltage and kilovoltage radiation energies. Med
Phys 2005;32(11):3350–4.
7. Butson MJ, Peter K, Metcalfe PE. Effects of read-out light
sources and ambient light on radiochromic ﬁlm. PMB
1998;43(8):2407.
8. Rivard MJ, Coursey BM, DeWerd LA, et al. Update of AAPM
Task Group No. 43 Report: a revised AAPM protocol for
brachytherapy dose calculations. Med Phys 2004;31(3):633–74.
9. Meigooni A. Recent developments in brachytherapy source
dosimetry. IJRR 2004;2(3):97–105.
0. Perez-Calatayud J, Ballester F, Das RK, et al. Dose calculation
for photon-emitting brachytherapy sources with average
energy higher than 50 keV: report of the AAPM and ESTRO.
Med  Phys 2012;39(5):2904–29.
1. Melhus CS, Rivard MJ. Approaches to calculating AAPM TG-43
brachytherapy dosimetry parameters for 137Cs, 125I, 192Ir,
103Pd, and 169Yb sources. Med Phys 2006;33(6):
1729–37.2. Toossi M, Ghorbani M, Mowlavi A, Meigooni A. Dosimetric
characterizations of GZP6 60Co high dose rate brachytherapy
sources: application of superimposition method. Radiol Oncol
2012;46(2):170–8.
3iotherapy 2 1 ( 2 0 1 6 ) 480–486
3. Sina S, Faghihi R, Meigooni A, Mehdizadeh S, Zehtabian M,
Mosleh-Shirazi M. Simulation of the shielding effects of an
applicator on the AAPM TG-43 parameters of CS-137
Selectron LDR brachytherapy sources. IJRR 2009;7(3):135–40.
4. TECDOC I. 1274. Calibration of photon and beta ray sources used
in  brachytherapy. Guidelines on standardized procedures at
Secondary Standards Dosimetry Laboratories (SSDLs) and
Hospitals.  IAEA; 2002.
5. Devic S, Seuntjens J, Hegyi G, et al. Dosimetric properties of
improved GafChromic ﬁlms for seven different digitizers. Med
Phys 2004;31(9):2392–401.
6. Nath R, Anderson LL, Meli JA, Olch AJ, Stitt JA, Williamson JF.
Code of practice for brachytherapy physics: report of the
AAPM Radiation Therapy Committee Task Group No. 56. Med
Phys 1997;24(10):1557–98.
7. Kubo HD, Glasgow GP, Pethel TD, Thomadsen BR, Williamson
JF.  High dose-rate brachytherapy treatment delivery: report of
the AAPM Radiation Therapy Committee Task Group No. 59.
Med Phys 1998;25(4):375–403.
8. Meli JA, Meigooni AS, Nath R. On the choice of phantom
material for the dosimetry of 192Ir sources. Int J Radiat Oncol
1988;14(3):587–94.
9. Lipin´ska J, Zwierzchowski G. Dosimetric veriﬁcation of the
dose distribution in pulsed dose rate brachytherapy. RPOR
2006;11(5):223–8.
0. Kohr P, Siebert F-A. Quality assurance of brachytherapy
afterloaders using a multi-slit phantom. PMB
2007;52(17):N387.
